Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies-Reference-Cited by-同舟云学术

Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies

Published:2020-04 Issue:4 Volume:15 Page:618-627
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Chung Hyun Cheol,Piha-Paul Sarina A.,Lopez-Martin Jose,Schellens Jan H.M.,Kao Steven,Miller Wilson H.,Delord Jean-Pierre,Gao Bo,Planchard David,Gottfried Maya,Zer Alona,Jalal Shadia I.,Penel Nicolas,Mehnert Janice M.,Matos Ignacio,Bennouna Jaafar,Kim Dong-Wan,Xu Lei,Krishnan Suba,Norwood Kevin,Ott Patrick A.

Funder

Merck Sharp and Dohme

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference32 articles.

1. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database;Govindan;J Clin Oncol,2006

2. Small cell lung cancer: state of the art and future perspectives;Stupp;Lung Cancer,2004

3. Unravelling the biology of SCLC: implications for therapy;Sabari;Nat Rev Clin Oncol,2017

4. Maintenance chemotherapy in small-cell lung cancer: long-term results of a randomized trial. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group;Giaccone;J Clin Oncol,1993

5. Systematic review of topotecan (Hycamtin) in relapsed small cell lung cancer;Riemsma;BMC Cancer,2010

Cited by 277 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Study design and rationale for IFCT- 2203 TAXIO: A study that aims to evaluate the effectiveness of a first-line chemotherapy regimen without etoposide, combined with durvalumab, for patients with extensive disease small cell lung cancer;Respiratory Medicine and Research;2024-11

2. Advances in predictive biomarkers associated with immunotherapy in extensive-stage small cell lung cancer;Cell & Bioscience;2024-09-12

3. Integration of clinical and blood parameters in risk prognostication for patients receiving immunochemotherapy for extensive stage small cell lung cancer: real-world data from two centers;BMC Medicine;2024-09-11

4. Characteristics of molecular subtypes and cinical outcomes in the immunotherapy Queue of extensive-stage small cell lung cancer patients;BMC Pulmonary Medicine;2024-08-29

5. DB-1314, a novel DLL3-targeting ADC with DNA topoisomerase I inhibitor, exhibits promising safety profile and therapeutic efficacy in preclinical small cell lung cancer models;Journal of Translational Medicine;2024-08-14